Cognition Therapeutics Files 8-K

Ticker: CGTX · Form: 8-K · Filed: Oct 1, 2024 · CIK: 1455365

Cognition Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyCognition Therapeutics INC (CGTX)
Form Type8-K
Filed DateOct 1, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, financials, sec-filing

TL;DR

Cognition Therapeutics filed an 8-K on Oct 1st, likely with financial updates.

AI Summary

Cognition Therapeutics, Inc. filed an 8-K on October 1, 2024, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. The company is incorporated in Delaware and its principal executive offices are located in Purchase, NY.

Why It Matters

This 8-K filing indicates that Cognition Therapeutics, Inc. is making important disclosures and submitting financial information to the SEC, which could impact investor understanding of the company's current status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for disclosures and exhibits, not indicating immediate significant financial distress or major corporate events.

Key Numbers

Key Players & Entities

FAQ

What specific events triggered this 8-K filing?

The filing indicates it is for 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', suggesting routine disclosures and financial reporting rather than a single triggering event.

When was the earliest event reported in this filing?

The earliest event reported was on October 1, 2024.

Where are Cognition Therapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 2500 Westchester Avenue, Purchase, NY 10577.

What is the company's state of incorporation?

The company is incorporated in Delaware.

What is the SEC file number for Cognition Therapeutics, Inc.?

The SEC file number is 001-40886.

Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-10-01 06:02:04

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that Cognition Therapeutics, Inc. may use from time to time in presentations or discussions with investors, analysts, and other parties. The information in this Item 7.01 (including Exhibit 99.1) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise Act of 1933, as amended, or the Exchange Act.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Investor presentation of Cognition Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COGNITION THERAPEUTICS, INC. Date: October 1, 2024 By: /s/ Lisa Ricciardi Name: Lisa Ricciardi Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing